At #NIH we continue to look for ways to streamline the process for finding safe, effective treatments for #COVID19. To that end, the #ACTIV-5 Big Effect Trial launched today to test medicines in a way that allows us to quickly identify the most promising
launches ACTIV5/BET (big effect trial)! Will enroll hospitalized patients across 40 U.S sites. Adaptive RCT, 100 per study arm. Start w/ risankizumab vs. lenzilumab vs. placebo (all in combination with remdesivir)